The neuroprotective efficacy of the DPP-4 inhibitor linagliptin against stroke is not mediated by GLP-1 receptor activation

被引：0
|
作者：
Darsalia, V. [1 ]
Larsson, M. [1 ]
Nathanson, D. [1 ]
Drucker, D. J. [2 ,3 ]
Nystrom, T. [1 ]
Klein, T. [4 ]
Patrone, C. [1 ]
机构：
[1] Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Internal Med, Stockholm, Sweden
[2] Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5S 1A1, Canada
[3] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5S 1A1, Canada
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
71
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [31] DPP-4-Hemmer und GLP-1-Rezeptor-AgonistenKardiovaskuläre Effekte DPP-4 inhibitors and GLP-1 receptor agonistsCardiovascular effects
    M. A. Nauck
    M. S. Abd El Aziz
    J. J. Meier
    Der Diabetologe, 2016, 12 : 184 - 194
  • [32] Blocking GLP-1 action with exendin [9-39] to determine the contribution of GLP-1 to the insulinotropic effects of the DPP-4 inhibitor vildagliptin
    Nauck, M. A.
    Kind, J.
    Deacon, C. F.
    Holst, J. J.
    He, Y.
    Broschag, M.
    Vardarli, I.
    Kjems, L.
    Foley, J.
    DIABETOLOGIA, 2011, 54 : S108 - S108
  • [33] Efficacy and safety of once-weekly GLP-1 RA in patients with type 2 diabetes treated with DPP-4 inhibitor
    Murakami, Masako
    Hirahara, Naoko
    Morita, Hiroshi
    Sasaki, Shigekazu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S105 - S105
  • [34] Incretin-related drugs and cardiovascular events: A comparison of GLP-1 analogue and DPP-4 inhibitor
    Higashi, Yukihito
    JOURNAL OF CARDIOLOGY, 2017, 69 (3-4) : 508 - 510
  • [35] The role of GLP-1 in type 2 diabetes (T2D): effects of DPP-4 inhibition and GLP-1 receptor blockade
    Aulinger, B. A.
    de Heer, J.
    Bedorf, A.
    Kutscherauer, G.
    Goeke, B.
    Schirra, J.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (03)
  • [36] Comparison between Clinical Efficacy of DPP-4 Inhibitors and GLP-1 Analogs in Type 2 Diabetics
    Faber-Heinemann, G.
    DIABETES STOFFWECHSEL UND HERZ, 2012, 21 (06): : 357 - 368
  • [37] The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain A Comparison With Glimepiride
    Darsalia, Vladimer
    Ortsater, Henrik
    Olverling, Anna
    Darlof, Emilia
    Wolbert, Petra
    Nystrom, Thomas
    Klein, Thomas
    Sjoholm, Ake
    Patrone, Cesare
    DIABETES, 2013, 62 (04) : 1289 - 1296
  • [38] Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
    Neumiller, Joshua J.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2009, 49 : S16 - S29
  • [39] From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
    Dicembrini, Ilaria
    Pala, Laura
    Rotella, Carlo Maria
    EXPERIMENTAL DIABETES RESEARCH, 2011,
  • [40] High DPP-4 Concentrations in Adolescents Are Associated With Low Intact GLP-1
    Stenlid, Rasmus
    Manell, Hannes
    Halldin, Maria
    Kullberg, Joel
    Ahlstrom, Hakan
    Manukyan, Levon
    Weghuber, Daniel
    Paulmichl, Katharina
    Zsoldos, Fanni
    Bergsten, Peter
    Forslund, Anders
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (08): : 2958 - 2966
12345